

# 40年の歴史を持つ医薬品



**MERGERSCORP**

## 40

同社は1982年、インド・パンジャブ州で原薬製造を目的に設立された。

同社は医薬品原薬（API）製造会社で、医薬品製造にこれらの製品を使用する製薬業界の大手数社の原料を製造している。

ファイザー、アボット、シプラ、グレンマーク、マクレオッズ、アリストなどの企業に製品を供給している。

同社は抗生物質、ビタミン剤、抗凝固剤から眼科用製品まで幅広い製品を提供している。

また、ISO、ZED、GMPなど、国内外の規制機関による監査も受けている。

事業は、新規の標的療法に作用し、副作用がないことを保証する組換えタンパク質の特許技術に取り組んでいる。現在は、ハイエンドの新規分子に重点を置いている。

#### 学問

当社は現在、幹細胞による若返り療法の実験的研究を行っており、副作用のない薬物療法の未来も約束している。

#### バイオテクノロジー

同社は、標的ヒト治療タンパク質の分野で重要なバイオテクノロジー研究活動に従事している。

現在の研究テーマは、喘息やアレルギーの患者を治療する一方で、肥満細胞症や好塩基球性白血病にも効果がある新薬を開発することである。

#### チーム

チームは、化学者、薬剤師、バイオ技術者、品質管理者、研究開発専門家、倉庫管理担当者など、100人の賢明な人材で構成されている。

65% インド / 35% その他の地域 / ヨーロッパ

25 OEM製品 / 医薬品有効成分原料

#### 抗生物質

ISO9001、EU規格（FDAなし）

#### TARGET PRICE

\$40,000,000

#### GROSS REVENUE

\$25,000,000

#### EBITDA

\$3,000,000

#### BUSINESS TYPE

製薬

#### ESTABLISHED

1989

#### SUPPORT & TRAINING

12ヶ月

#### REASON FOR SELLING

退職

#### COUNTRY

インド

#### BUSINESS ID

L#20210013

年率20%以上

従業員100人以上

化学エンジニアの経歴

売上高2500万ドル／EBITDA300万ドル

お客様



*The information contained herein does not constitute an offer to sell or a solicitation of an offer or a recommendation to purchase securities under the securities laws of any jurisdiction, including the United States Securities Act of 1933, as amended, or any US state securities laws, or a solicitation to enter into any other transaction*

*The projected financial information contained in the Memorandum is based on judgmental estimates and assumptions made by the management of the target Company, about circumstances and events that have not yet taken place. Accordingly, there can be no assurance that the projected results will be attained. In particular, but without prejudice to the generality of the foregoing, no representation or warranty whatsoever is given in relation to the reasonableness or achievability of the projections contained in the Memorandum or in relation to the bases and assumptions underlying such projections and you must satisfy yourself in relation to the reasonableness, achievability and accuracy thereof.*

*By delivering this Memorandum, neither MergersUS Inc., nor its authorized agents are making any recommendations regarding the acquisition or strategies outlined herein. Interested parties shall exercise independent judgment in, and have sole responsibility for, determining whether an acquisition of the Company is suitable for them, and neither MergersUS Inc, nor its authorized agents have responsibility to, and will not, monitor the condition of interested parties to determine that an acquisition is or remains suitable for them. Among other things, suitability of an acquisition will depend upon an interested party's investment and business plans and financial situation.*

*This document is prepared for information purposes only. It is made available on the express understanding that it will be used for the sole purpose of assisting the recipients to decide whether they wish to proceed with a further investigation of the Proposed Transaction.*

*The recipients realize and agree that this document is not intended to form the basis of any investment decision or any other appraisal or decision regarding the Proposed Transaction, and does not constitute the basis for the contract which may be concluded in relation to the Proposed Transaction.*

*All information contained in this document may subsequently be updated and adjusted. MergersUS Inc. has not independently verified any of the information contained herein or on which this document is based. Neither the Company, nor its management or shareholders, nor MergersUS Inc. , nor any of their respective directors, partners, officers, employees or affiliates make any representation or warranty (express or implied) or accept or will accept any responsibility or liability regarding or in relation to the accuracy or completeness of the information contained in this document or any other written or oral information made available to any interested party or its advisers. Any liability in respect of any such information or any inaccuracy in or omission from the document is expressly disclaimed.*

## MERGERSCORP

© 2026 MergersCorp M&A International. All rights reserved.

© 2026 MergersCorp M&A International. MergersCorp™ M&A International is the collective brand name of independent affiliates of MergersCorp M&A International. For more details on the nature of our affiliation, please visit us on our website <https://www.mergerscorp.com/disclaimer>. MergersCorp M&A International is not a registered broker-dealer under the U.S. securities laws. MergersCorp M&A International does not offer or sell securities or provide investment advice or underwriting services. The articles or publications contained in this presentation are not intended to provide specific business or investment advice. The author or MergersCorp M&A International shall not be liable for any errors or omissions, or for any loss suffered by any person or organization acting or refraining from acting as a result of the content of this website. It is recommended that specific independent advice be sought before making any business or investment decision.

**MERGERSCORP**

[WWW.MERGERSCORP.COM](http://WWW.MERGERSCORP.COM)